MSD Korea, Daewoong seeking strategic alliance for Januvia

Published: 2008-04-16 07:00:00

Updated: 2008-04-16 07:00:00

MSD Korea and Daewoong Pharm have recently agreed to jointly market Januvia (sitagliptin phosphate) under their second strategic alliance following Fosamax Plus last March.

Approved by the Korea Food and Drug Administration last October, Januvia is an oral diabetes medication in a new class of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK